Eli Lilly and Novo Nordisk, leading companies in weight-loss drugs, are showing contrasting stock performances. Eli Lilly's stock has surged by 47% over the past year, while Novo Nordisk's has dropped by over 40%. This divergence suggests that Wall Street has currently favored Eli Lilly.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.

By Mackenzie Tatananni

and Callum Keown

Resize

Reprints

In this article

LLY

NVO

Eli Lilly stock is up 47% over the past year, while Novo is down more than 40% over that period. (Daniel Acker/Bloomberg)

Eli LillyandNovo Nordiskmay be the undisputed duopoly of weight-loss drugs, but their diverging stock performance suggests Wall Street has picked a favorite—for now.

Barron’s Investor Circle

Chart of the Day: The U.S. Dollar at a Critical Inflection Point \ \ 0·15 hours ago\ \ On the Radar: Yelp \ \ 0·16 hours ago\ \ Chart of the Day: Teva Pharmaceutical’s Technical Setup Continues to Improve \ \ 0·Jun 5, 2026\ \ Chart of the Week: Freeport-McMoRan Builds Strong Base, Suggesting Imminent Breakout. \ \ 0·Jun 4, 2026\ \

Subscribe Learn More

Read Original at Barron's →

Eli Lilly, Novo Both Share Weight-Loss Drug News. Only One Stock Is Rising.

Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising.